Pediatric Blood Cultures and Antibiotic Resistance: An Overview.
Anti-Bacterial Agents
/ pharmacology
Bacteremia
/ microbiology
Blood Culture
/ methods
Candida
/ drug effects
Carbapenems
/ pharmacology
Child
Drug Resistance, Bacterial
/ drug effects
Gram-Negative Bacteria
/ drug effects
Humans
India
Klebsiella pneumoniae
/ drug effects
Methicillin-Resistant Staphylococcus aureus
/ drug effects
Microbial Sensitivity Tests
/ methods
Salmonella
Typhoid Fever
/ drug therapy
AMR
Etiology
PICU
Pediatric blood culture
Surveillance
Journal
Indian journal of pediatrics
ISSN: 0973-7693
Titre abrégé: Indian J Pediatr
Pays: India
ID NLM: 0417442
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
05
11
2019
accepted:
06
11
2019
pubmed:
22
12
2019
medline:
24
11
2020
entrez:
22
12
2019
Statut:
ppublish
Résumé
Bloodstream infections (BSI) due to multidrug-resistant organisms, especially from pediatric intensive care units (PICU), are being increasingly reported across the world. Since BSI is associated with high mortality, it is essential to treat these infections early with appropriate antibiotics. Surveillance of etiology and emerging antimicrobial resistance (AMR) is considered an important step in the formulation of antibiotic policy for early treatment and judicious use of antibiotics. In this review on etiology and its antibiogram in community acquired BSI, S. typhi followed by S. paratyphi A were the major bacterial isolates. Quinolone resistance of more than 90% in Salmonella is now reported from all over India. Ceftriaxone remains the drug of choice for enteric fever due to its 100% susceptibility. In PICU there is an emergence of candidemia due to non-albicans candida which are now predominant isolates at few centers. BSI due to gram-negative bacteria, mostly by Klebseilla pneumoniae and gram-positive cocci (S. aureus) are the other major pathogens commonly observed in BSI from PICU. There is a high prevalence of antimicrobial resistance to commonly used antibiotics like ampicillin (94.9%-90.7%), cefotaxime (92.4%-71.4%), piperacillin-tazobactum (31.2%-27.5%) and levofloxacin (42.4%-39.8%). Resistance to carbapenems, primarily due to bla
Identifiants
pubmed: 31863394
doi: 10.1007/s12098-019-03123-y
pii: 10.1007/s12098-019-03123-y
pmc: PMC6974494
doi:
Substances chimiques
Anti-Bacterial Agents
0
Carbapenems
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
125-131Commentaires et corrections
Type : ErratumIn
Type : CommentIn
Références
J Korean Med Sci. 2010 Jul;25(7):992-8
pubmed: 20592888
Indian Pediatr. 2017 Dec 15;54(12):1021-1024
pubmed: 28849764
J Med Microbiol. 2008 Jul;57(Pt 7):881-886
pubmed: 18566147
Braz J Infect Dis. 2014 May-Jun;18(3):245-51
pubmed: 24389282
J Clin Microbiol. 2007 Nov;45(11):3546-8
pubmed: 17881544
Indian J Pediatr. 2015 Jun;82(6):530-6
pubmed: 25429999
Eur J Clin Microbiol Infect Dis. 2017 Dec;36(12):2399-2404
pubmed: 28785823
Indian J Med Res. 2015 Aug;142(2):130-8
pubmed: 26354210
Indian J Med Res. 2012 Dec;136(6):997-1003
pubmed: 23391796
Eur J Pediatr. 2004 Sep;163(9):530-5
pubmed: 15241687
Lancet Infect Dis. 2008 Jan;8(1):19-31
pubmed: 18156087
Int J Infect Dis. 2006 Nov;10(6):434-8
pubmed: 16978898
Infect Control Hosp Epidemiol. 2018 Jan;39(1):1-11
pubmed: 29249216
Clin Infect Dis. 2004 Jun 15;38(12):1724-30
pubmed: 15227618
J Trop Pediatr. 2007 Apr;53(2):87-92
pubmed: 17151083
J Med Microbiol. 2012 Jul;61(Pt 7):1032-1033
pubmed: 22442289
Pediatrics. 2002 Aug;110(2 Pt 1):285-91
pubmed: 12165580
Rev Infect Dis. 1983 Jan-Feb;5(1):35-53
pubmed: 6828811
Clin Microbiol Rev. 1997 Jul;10(3):444-65
pubmed: 9227861
J Antimicrob Chemother. 2008 Oct;62(4):837-42
pubmed: 18617509
Clin Infect Dis. 2016 May 15;62(10):e51-77
pubmed: 27080992
PLoS Negl Trop Dis. 2016 Apr 15;10(4):e0004616
pubmed: 27082958
Indian J Pediatr. 2012 May;79(5):647-9
pubmed: 22290631
Indian J Cancer. 2014 Oct-Dec;51(4):438-41
pubmed: 26842152
Pediatr Infect Dis J. 2017 Jun;36(6):e161-e166
pubmed: 28005691
J Pediatric Infect Dis Soc. 2017 Sep 1;6(3):e62-e68
pubmed: 28339675
Emerg Infect Dis. 2009 Sep;15(9):1533-5
pubmed: 19788837
Bull World Health Organ. 2008 Apr;86(4):260-8
pubmed: 18438514
Indian J Med Res. 2013 Feb;137(2):363-9
pubmed: 23563381
Indian J Pediatr. 2008 Jan;75(1):25-30
pubmed: 18245931
Emerg Infect Dis. 2014 Jul;20(7):1170-5
pubmed: 24959688
Clin Infect Dis. 1999 Dec;29(6):1483-8
pubmed: 10585800
Pediatr Infect Dis J. 2015 Jul;34(7):734-41
pubmed: 25607829
Lancet Infect Dis. 2016 Feb;16(2):161-8
pubmed: 26603172